Omthera Pharmaceuticals, Inc. 4
4 · Omthera Pharmaceuticals, Inc. · Filed Jul 18, 2013
Insider Transaction Report
Form 4
Wisler Gerald
DirectorPresident and CEO
Transactions
- Disposition to Issuer
Common Stock
2013-07-18−661,546→ 0 total - Disposition to Issuer
Common Stock
2013-07-18−331,963→ 0 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2013-07-18−26,382→ 0 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2013-07-18−331,963→ 0 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2013-07-18−26,382→ 0 total(indirect: By Trust)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Omthera Pharmaceuticals, Inc. (the "Company"), Zeneca, Inc. and KAFA Acquisition Corp., dated May 27, 2013, each share of the Company's common stock was exchanged for $12.70 in cash, without interest, less any applicable withholding taxes, plus one contractual contingent value right, which represents the right to receive contingent payments of up to approximately $4.70 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods.
- [F2]These shares are held in a trust for the benefit of one of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, except to the extent of the reporting person's pecuniary interest, if any, therein, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.